ReviewJournal of substance use and addiction treatment2024
Payment-related barriers to medications for opioid use disorder: A critical review of the literature and real-world application.
Review in Journal of substance use and addiction treatment, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Barriers to opioid replacement therapy in pregnant women with opioid use disorder: a systematic review.Substance abuse treatment, prevention, and policy · 2025Pooled it
- Continuity of Medications for Opioid Use Disorder in States With and Without Medicaid Prescription Cap Policies.Medical care · 2026Article
- County-Level Variation in Substance Use Disorder Service Utilization by Insurance Payers and Self-Pay in the United States.The Journal of clinical psychiatry · 2026Article
- Policy and Payment Factors Influencing Adoption of Low-Barrier Buprenorphine Treatment.JAMA network open · 2026Article
- Reducing Buprenorphine Misinformation as a Strategy to Improve Adoption in Primary Care.Substance use & misuse · 2026Article
- The Association Between Receiving Medications for Opioid Use Disorder and Human Immunodeficiency Virus Testing: Findings From the Rural Opioid Initiative.Journal of addiction medicine · 2026Article
- Low-threshold Buprenorphine: Proposing the Ideal Service Model to Engage People With Severe Opioid Use Disorder.Journal of addiction medicine · 2026Article
- Opioid Use Disorder Care Presentations After High-deductible Health Plan Enrollment.Journal of addiction medicine · 2026Article
- Retention among Medicaid beneficiaries in opioid treatment programs in California.Journal of substance use and addiction treatment · 2026Article
- Article
- Article
- Allocative efficiency of opioid overdose prevention strategies for people incarcerated in New Jersey.Harm reduction journal · 2025Article
- The hidden costs of 'free' treatment: A cross-sectional study of patient-incurred costs for daily methadone maintenance treatment in Nairobi, Kenya.PLOS mental health · 2025Article
- Opportunities to Innovate Health Policy and Practice to Improve Opioid Use Disorder Care for Older Adults Across the Care Continuum.Innovation in aging · 2025Article
- Medication Approaches for Patients With Opioid Use Disorders: Differences Between Primary Care Clinics and Specialty Addiction Treatment Programs.Journal of addiction medicineArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundThe national opioid crisis continues to intensify, despite the fact that opioid use disorder (OUD) is treatable and opioid overdose deaths are preventable through first-line treatment with medications for opioid use disorder (MOUD). This study identifies and categorizes payment-related barriers that impact MOUD access and retention from both the provider and patient perspectives and provides insight into how these barriers can be addressed.
methodsWe performed a critical review of the literature (peer-reviewed studies and relevant documents from the gray literature) to identify payment-related access and retention barriers to MOUD. We used the results of this review to develop an analytic framework to understand how payment impacts MOUD access and retention for both providers and patients. In addition, we reviewed action plans developed by Massachusetts communities that participated in the Healing Communities Study (HCS) to analyze which payment-related barriers were addressed through the study.
resultsWe identified 18 payment-related barriers that patients or providers face when initiating or continuing MOUD with either methadone or buprenorphine in Opioid Treatment Programs (OTP) and non-OTP settings. Patient-related barriers mainly relate to health insurance coverage or the design of health plans (e.g., cost sharing, covered benefits) resulting in direct (medical and non-medical) and indirect costs that can affect both access and retention, especially as they relate to services provided in OTPs. Provider-related barriers include low reimbursement and administrative burden and are most likely to impact access to MOUD. Evidence-based strategies to expand MOUD as part of the HCS in Massachusetts targeted about half of the patient and provider payment-related barriers identified.
conclusionPatients and providers face an array of payment-related barriers that impact access to and retention on MOUD, most of which relate to inadequate health insurance coverage, features of health plans, and key federal and state policies. As new regulatory policies are enacted that expand access to MOUD, such as greater flexibility in OTPs and MOUD delivered via telehealth, it will be important to align these delivery changes with payment reform involving payers, providers, and policymakers.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.